Pacira BioSciences, Inc. Operating Income Loss

• Pacira BioSciences, Inc. showed an increase of +126.2% in Operating Income Loss from 2024 to 2025.
• This data is from Pacira BioSciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), Pacira BioSciences, Inc.'s Operating Income Loss has grown by 167.2%.
• Historical annual values: Fiscal year 2025: $19.19 million | Fiscal year 2024: -$73.37 million | Fiscal year 2023: $87.68 million | Fiscal year 2022: $60.02 million | Fiscal year 2021: $89.92 million | Fiscal year 2020: $46.35 million | Fiscal year 2019: $10.48 million | Fiscal year 2018: $15.92 million | Fiscal year 2017: -$24.94 million | Fiscal year 2016: -$32.02 million | Fiscal year 2015: $9.46 million | Fiscal year 2014: -$5.17 million | Fiscal year 2013: -$53.29 million | Fiscal year 2012: -$49.30 million | Fiscal year 2011: -$39.10 million | Fiscal year 2010: -$22.71 million | Fiscal year 2009: -$28.55 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026